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Introduction 
For decades, the scientific community has been perplexed about the incongruent 
relationship of blood cholesterol concentrations and risk of coronary heart disease (CHD). 
This is borne out of the strong observational relationships of both low- (LDL-C) and high-
(HDL-C) density lipoprotein cholesterol with risk of CHD. While a causal role for LDL-C is 
well-established from multiple randomized trials of drugs that alter LDL-C, the role of HDL-C 
remains much less clear. The enzyme cholesterol ester transfer protein (CETP) exchanges 
cholesterol from HDL particles to very low density lipoprotein particles in exchange for 
triglycerides and treatment with potent CETP inhibitors leads to an elevation of HDL-C and a 
reduction in Friedewald-measured LDL-C. Initial phase III randomized controlled trials (RCTs) 
of CETP inhibitors failed due to lack of efficacy and/or adverse effects, but the REVEAL trial 
recently reported a beneficial effect for CHD.1 In this Comment, we summarise the evidence 
for CETP inhibitors in the context of genetic studies. 
 
HDL-C as a predictor of CVD 
Traditional observational studies provide strong evidence that HDL-C is independently 
inversely associated with future risk of CHD and stroke in prospective cohorts. The 
association of HDL-C with risk of CHD remains present even when adjusting for triglycerides 
and other potential confounders.  However, whereas the path to showing LDL-C to be causal 
in CHD has been smooth with orthogonally-targeted pharmaceutical agents (statins, 
ezetimibe and PCSK9 inhibitors) providing consistent evidence from RCTs, the path has been 
much more tortuous for drugs principally targeting HDL-C. The robust association of HDL-C 
with CHD in observational data does provide clinical utility for disease prediction; indeed 
HDL-C is included in many risk prediction scores. However, utility for disease prediction is 
quite distinct to causality. Despite the prevailing view being that the evidence for causality 
of HDL-C was very strong (as evidenced by the huge investment in RCTs) over quarter of a 
century ago it was demonstrated that the statistical robustness of the epidemiological 
evidence was suspect2.  More recently, studies have sought to clarify the role that HDL-C has 
in cardiovascular diseases (CVD) using both genetic and interventional study designs. 
 
Genetic evidence of HDL-C 
The most notable Mendelian randomization (MR) study of HDL-C by Voight and colleagues 
in 2012 did not provide evidence of causation (as summarised in a recent MR review3). From 
a modern MR perspective, the approach by Voight et al could be considered limited as the 
instrument consisted of only 14 single nucleotide polymorphisms (SNPs) that had been 
manually pruned to remove SNPs that also showed associations with LDL-C and TG: in the 
two-sample MR design, this could lead to a false negative association in the presence of 
weak instrument bias, and the selection of the SNPs in such a way may not be objective and 
could introduce bias3. However, subsequent studies using many larger sets of SNPs 
identified from GWAS of HDL-C and more contemporary MR approaches (that take into 
account genetic pleiotropy) have also shown a neural association of HDL-C with CHD risk.4 
This has led to the prevailing interpretation that circulating levels of HDL-C are unlikely to 
play an important role in the aetiology of CHD. 
 
Genetic evidence of CETP 
MR of a biomarker (such a HDL-C) is quite distinct to MR of a drug target, as drug targets 
tend not to show specificity for the exposure of interest. Early studies provided weak 
evidence that CETP genetic variants were linked to CHD risk, however more recent large-
scale evidence provides robust associations, including the identification of a variant in CETP 
associated with CHD at P = 9.8x10-9 in a recent hypothesis-free GWAS.5 Furthermore, a very 
recent factorial MR study6 provided new insights that predicted the clinical effect of CETP 
inhibition, when given with a statin, might be exaggerated if LDL-C is used as a marker of 
CETP drug efficacy as opposed to apolipoprotein B, as reported in REVEAL.1 
 
Treatment trials of CETP inhibitors 
The first phase III trial of a CETP inhibitor (ILLUMINATE7) randomized 15,067 patients at high 
cardiovascular risk to torcetrapib or placebo. Torcetrapib raised HDL-C by 72% and lowered 
LDL-C by 25% but the trial was terminated due to 25% higher risk of major vascular events in 
those randomized to torcetrapib, linked to elevated systolic blood pressure (SBP). Of note, 
higher SBP associations were also identified for all other CETP inhibitors tested in phase III 
RCTs (including dalcetrapib, evacetrapib and anacetrapib). dal-OUTCOMES8  randomized 
15,871 patients with a recent acute coronary syndrome to dalcetrapib or placebo. 
Dalcetrapib increased HDL-C by 31-40% but had minimal effect on LDL-C and dal-
OUTCOMES was terminated due to futility, with the hazard ratio (HR) for the primary 
endpoint of major vascular events being 1.04 (0.93,1.16) for dalcetrapib vs placebo. In the 
subsequent ACCELERATE trial9, 12,092 with established vascular disease were randomized 
to receive evacetrapib or placebo. Evacetrapib, an efficacious CETP inhibitor, increased HDL-
C by 132% and lowered LDL-C by 37%, but ACCELERATE was also terminated after an 
average 25 months of treatment owing to futility, with the HR of the primary endpoint of 
major vascular event for evacetrapib vs placebo being 1.01 (95%CI: 0.91, 1.11). Most 
recently, and as a surprise to the cardiovascular community, the REVEAL1 trial of 
anacetrapib, another potent CETP inhibitor, reported a beneficial effect. In REVEAL, 30,449 
patients with prior vascular disease were randomized to anacetrapib or placebo. 
Anacetrapib treatment led to a 104% increase in HDL-C and a 17 or 41% reduction in LDL-C 
(for LDL-C measured by beta-quantification and direct method, respectively) and yielded a 
HR of 0.91 (0.85 to 0.97) of major coronary events, compared to placebo.1 
 
Putting the evidence together 
How do we explain the incongruent findings between multiple trials of CETP inhibitors, CETP 
genetics and HDL-C? First, the findings from REVEAL1 do not change the prevailing notion 
that circulating levels of HDL-C are unlikely to play an important role in the aetiology of 
CHD. To expand, CETP inhibitors that had no large effect on atherogenic lipoproteins (LDL-C 
or apolipoprotein B) had no association with CHD. Second, the magnitudes of effect for both 
non-HDL-C and corresponding risks of CHD reported in REVEAL are entirely consistent with 
those from treatment trials of statins, ezetimibe and PCSK9 inhibitors (Figure), and the 
genetic associations that correspond to these drug targets line up on a steeper slope which 
is expected given that the effect of atherogenic lipoproteins on cardiovascular risk is 
accumulated over a lifetime. Third, the neutral finding in ACCELERATE of evacetrapib, a drug 
that did have strong effects on non-HDL-C, is likely to have arisen from premature 
termination of the trial, as exemplified by the stratification of findings from REVEAL by years 
of follow-up: at 2 years, the estimate for major coronary events from REVEAL was RR 0.96 
(0.84–1.10) which overlaps the major vascular estimates from ACCELERATE (1.01; 0.91 to 
1.12). Furthermore, in REVEAL, the estimate for major coronary events was stronger than 
major vascular events, meaning that ACCELERATE may also have been hindered by use of a 
primary endpoint comprising a composite that included elements that may have attenuated 
the association.  
Moving forward, key questions include: (i) the mechanism of increase in SBP that is seen in 
treatment with CETP inhibitors, which, with the exception of torcetrapib (where there was 
very likely an excess SBP effect), the modest SBP signal appears to be in ratio to the degree 
of HDL-C raising and could therefore be target-mediated; (ii) whether therapeutic inhibition 
of CETP leads to age-related macular degeneration, as predicted by genetic studies10, but for 
which REVEAL was underpowered to detect; (iii) whether CETP inhibitors alter risk of 
diabetes (a modest beneficial effect was seen in both REVEAL and ACCELERATE); (iv) which 
patients might derive clinical benefit from CETP inhibitors; and,  (v) the cost-effectively of 
such treatment. Certainly, the findings from REVEAL brings to a close the long-standing 
worrisome discordance between multiple MR findings (that anticipated cardiovascular 
benefit from therapeutic inhibition of CETP) and multiple phase III clinical trials (that, prior 
to REVEAL, showed no such benefit). For lipidoligists, the accumulating data point towards a 
unifying theory of apolipoprotein B driving CHD, and it may be back to the drawing board 
for HDL. 
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Figure Legends 
 
 
Figure. Treatment trials of drugs and natural trials of genes that modify non-HDL-C and 
risk of coronary heart disease.  
Treatment trials are represented by circles and solid vertical lines, whereas genetic proxies 
are represented by squares and dashed vertical lines. The three cholesterol treatment 
trialists’ (CTT) collaboration values (plotted in mint green) from left to right are: (i) 5 more-
vs-less statin trials; (ii) 17 statin-vs-placebo trials with non-HDL differences <50 mg/dL; and, 
(iii) 4 statin-vs-placebo trials with non-HDL differences >50mg/dL and, together with the 
data from REVEAL, are derived from Figure S5 of the REVEAL trial publication1 with 
estimates obtained using ‘PlotDigitizer’ (http://plotdigitizer.sourceforge.net/). Values for 
the genetic variants are taken from Figure 2C in Ference et al,6 scaled to the same difference 
in non-HDL-C as the corresponding treatment trials, using apolipoprotein B as a proxy for 
non-HDL-C. CHD end-points in trials comprise: REVEAL and CCT: coronary death or MI; 
IMPROVE-IT and FOURIER: MI. End-point in Ference et al6 is MI, coronary revascularization, 
stroke or coronary death.  
